DELRAY
BEACH, Fla., Sept. 27,
2024 /PRNewswire/ -- The global Age-related
Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust
CAGR of 10.7%. This growth is driven by rising AMD prevalence
linked to lifestyle changes, increased R&D investment leading
to more drug approvals, and improved reimbursement policies. The
market is particularly expanding in developing countries and is
witnessing a shift towards innovative therapies like gene therapy.
However, challenges like high treatment costs and the off-label use
of drugs such as Avastin hinder market potential. Notably, Eylea
remains the leading product, while dry AMD therapies are expected
to grow rapidly due to escalating cases among the aging population.
North America is projected to be
the fastest-growing region, with significant annual AMD case
increases. Key players include Regeneron, Bayer, and Novartis,
among others, with recent developments indicating a strong focus on
new therapeutic solutions.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37446234
Browse in-depth TOC on "Age-related Macular
Degeneration (AMD) Drugs Market"
378 - Tables
54 - Figures
336 -
Pages
Based on molecules, the global Age-Related Macular
Degeneration (AMD) drugs market has been segmented into
Ranibizumab, Aflibercept, Faricimab, Pegcetacoplan, and other
molecules including conbercept, brolucizumab, avacincaptad pegol,
and bevacizumab-gamma among others. In 2023, aflibercept held the
largest share of the Age-Related Macular Degeneration (AMD) drugs
market by molecule. This large share of the molecule can be
attributed to the high adoption of this molecule for the treatment
of the wet or neovascular form of AMD. This adoption is due to the
high affinity of the molecule for VEGF proteins preventing
activation of native VEGF receptors and reducing angiogenesis and
vascular permeability. Moreover, the efficacy of the molecule is
supported by various research studies comparing the effectiveness
of this molecule to other molecules used for AMD treatment.
Additionally, the ongoing development of novel drug delivery
methods and biosimilars for this molecule further supports the
growth of the market of this molecule.
Based on the type of AMD, the global Age-Related Macular
Degeneration (AMD) drugs market has been segmented into wet AMD and
dry AMD. In 2023, the wet AMD disease segment accounted for the
largest share of the AMD market by type of AMD. The large share of
wet AMD can be attributed to the rising prevalence of this disease
affecting more than 20 million individuals globally. Reports from
leading pharmaceutical companies highlight that more than 200,000
cases of wet AMD are reported in the US every year. This increase
in wet AMD cases is attributed to the rising geriatric population
with the World Health Organization (WHO) estimating a 2x increase
in the number of individuals over 60 years of age by 2050. This
market is also supported by new entrants targeting patients earlier
in the disease cascade, with new drugs such as new entrants
targeting patients earlier in the disease cascade with new drugs
such as OPT-302 and KSI-301 being developed for the treatment of
this disease.
Based on end users, the global age-related macular
degeneration (AMD) drugs market has been segmented into hospitals,
specialty centers, and long-term care facilities. Hospitals
accounted for the largest share of the AMD drugs market by end user
in 2023. The large share of this segment is attributed to the
rising prevalence of AMD cases and the ability of hospitals to
provide advanced healthcare infrastructure and specialized
treatment capabilities that aid in the treatment of patients with
AMD. Furthermore, hospitals also support research that facilitates
the development of better treatment for various diseases including
AMD. Hospitals collaborate with pharmaceutical companies to ensure
the optimal availability of AMD drugs for patients while providing
comprehensive care, including diagnostics, treatment
administration, and patient monitoring to enhance treatment outcome
for the patients.
The key regional markets for age-related macular degeneration
(AMD) drugs market are North
America, Europe,
Asia Pacific, Latin America, Middle East and Africa. In 2023, North America accounted for the largest share
of the market. This can be attributed to the increasing AMD cases
in the region with reports from major pharmaceutical companies
highlighting the occurrence of more than 200,000 new cases of AMD
every year in the US. A rise in obesity, smoking, and poor diet in
this region further contributes to the increase in the number of
AMD cases. Additionally, an increase in the number of approvals for
AMD drugs in the region further supports the market growth.
Advanced healthcare infrastructure in these regions, including
access to specialists and diagnostic tools, supports early
detection and treatment.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37446234
The prominent players in the global Age-Related Macular
Degeneration (AMD) market are Regeneron Pharmaceuticals Inc. (US),
Bayer AG (Germany), F. Hoffmann-La
Roche Ltd (Switzerland), Novartis
AG (Switzerland), Apellis
Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma
Inc. (Japan), Biogen (US), STADA
Arzneimittel AG (Germany),
Formycon AG (Germany), Biocon.
(India), Outlook Therapeutics,
Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd.
(Israel), Chengdu Kanghong Biotech
Company (China) and Sandoz Group
AG (Switzerland). The market also
includes players, such as Stealth BioTherapeutics Inc. (US),
Ocular Therapeutix, Inc. (US), Opthea Limited (Australia), Kodiak Sciences Inc. (US),
Innovent (China), Bio-Thera
Solution (China), Alvotech
(Iceland), Alteogen Inc.
(South Korea), Shanghai Henlius
Biotech, Inc. (China), Amgen Inc.
(US), Ocumension Therapeutics. (China), and Adverum Biotechnologies, Inc.
(US), that have drug candidates in phase 3 clinical trials.
Regeneron Pharmaceuticals Inc. (US):
Regeneron Pharmaceuticals Inc. is a biotechnology company that
focuses on the development, manufacturing, and distribution of
therapeutic drugs such as Eylea and Eylea HD (high dose) in the US
for the treatment of various retinal disorders including wet
Age-Related Macular Degeneration (wAMD). Eylea is one of the most
adopted therapeutic drugs for the treatment of wet AMD across the
globe. The company has partnered with major pharmaceutical
companies such as Bayer AG to manufacture and distribute the drugs
outside the US. Regeneron has operations in over 12 countries
across the Asia Pacific,
Europe, and North America, and conducts clinical trials in
more than 60 countries. In 2023, the company allocated USD 96.2 million to improve Eylea HD, a higher
hose of its already successful AMD drug Eylea. This drug allows
patients to obtain similar therapeutic results with less number of
injections reducing the treatment burden on the patients. The
company has also developed innovative technologies like TRAPS and
VelociSuite, which are used for the development of bispecific
antibodies, essential for the development of next-generation
ophthalmic drugs.
F. Hoffmann-La Roche Ltd (Switzerland):
Roche is a major pharmaceutical company that offers three
FDA-approved drugs for the treatment of wet AMD among other retinal
diseases: Lucentis, Vabysmo, and Susvimo, the company also provides
Avastin (Bevacizumab) which is widely used as an off-label drug for
the treatment of wet AMD owing to its affordability. In 2023, the
company invested approximately 22% (USD 14.7
billion) of its annual revenue in R&D for the
development of new drugs and exploring advanced research methods,
including computational biology. The company has received marketing
approvals for its AMD drugs in many countries, with recent
expansions into markets like India. Roche's Genentech Ophthalmology Co-pay
Program helps cover drug and administration costs making treatments
more affordable. The company has operations in over 95 countries
and offers a wide range of therapeutic products for a variety of
diseases and disorders.
Novartis AG (Switzerland):
Novartis AG is a biotechnology company that focuses on the
development and distribution of innovative medicines across key
therapeutic areas, including cardiovascular, renal, metabolic,
immunology, neuroscience, ophthalmology, and oncology. In 2023,
Novartis became a pure-play innovative medicines company by
spinning off its Sandoz generic and biosimilar business unit. The
company strongly focuses on ophthalmology, and markets FDA-approved
drugs like Lucentis and Beovu (brolucizumab) for treating wet
Age-Related Macular Degeneration (AMD) across the globe. Novartis
is also conducting phase 3 clinical trials for Beovu to expand its
use for diabetic retinopathy, highlighting the company's focus on
innovation and expanding treatment options. The company operates in
over 130 countries and uses contract structures such as
pay-over-time and outcome-based agreements to make its products
more affordable and accessible to patients.
For more information, Inquire Now!
Related Reports:
Cardiac Monitoring Devices Market
Biomarkers Market
Biosimilars Market
Stem Cell Therapy Market
Life Science Instrumentation Market
Get access to the latest updates on AMD Drugs Companies
and Age-related Macular Degeneration Drugs Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of
America's best management consulting firms by Forbes, as per
their recent report.
MarketsandMarkets™ is a blue ocean alternative in
growth consulting and program management, leveraging a man-machine
offering to drive supernormal growth for progressive organizations
in the B2B space. We have the widest lens on emerging technologies,
making us proficient in co-creating supernormal growth for
clients.
Earlier this year, we made a formal transformation into one of
America's best management consulting firms as per a survey
conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are
substituting existing revenue streams in this decade alone. We work
with clients on growth programs, helping them monetize this
$25 trillion opportunity through our
service lines - TAM Expansion, Go-to-Market (GTM) Strategy to
Execution, Market Share Gain, Account Enablement, and Thought
Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a
disruptive ecosystem. Our insights and strategies are molded by our
industry experts, cutting-edge AI-powered Market Intelligence
Cloud, and years of research. The KnowledgeStore™ (our
Market Intelligence Cloud) integrates our research, facilitates an
analysis of interconnections through a set of applications, helping
clients look at the entire ecosystem and understand the revenue
shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us
on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan
Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL
33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo:
https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original
content:https://www.prnewswire.com/news-releases/amd-drugs-market-to-hit-usd-17-37-billion-by-2029-with-10-7-cagr--marketsandmarkets-302260905.html
SOURCE MarketsandMarkets